Enfusion's chief accounting officer sells $8,063 in stock

CHICAGO—Valeria Gutowski, Chief Accounting Officer at Enfusion, Inc. (NYSE:ENFN), a $1.32 billion market cap fintech company showing 15.8% revenue growth, recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Gutowski sold 796 shares of Class A Common Stock on January 7, 2025, at an average price of $10.13 per share, totaling approximately $8,063. InvestingPro analysis indicates the stock is trading near its Fair Value, with strong liquidity metrics and positive growth expectations.

The transaction was reported as a mandatory sale to cover tax withholding obligations related to the issuance of shares, rather than a discretionary trade by Gutowski. Following this transaction, Gutowski holds 34,803 shares of Enfusion stock. According to InvestingPro, which offers comprehensive analysis of 1,400+ US stocks through its Pro Research Reports, Enfusion maintains a healthy balance sheet with a current ratio of 3.62, indicating strong short-term financial stability.

In other recent news, Enfusion Inc. reported a successful third quarter in 2024, with a notable 15% increase in year-over-year revenue to $51.2 million and an adjusted EBITDA of $11.1 million. The company's annual recurring revenue (ARR) surpassed $200 million, marking a 14% year-over-year increase. Enfusion also gained 38 new clients, bringing the total to 894, and reported an average total value (ATV) of $229,000, up 5.7% year-over-year.

Revenue growth was significant across all regions, with the Americas at 17%, EMEA at 22%, and Asia-Pacific at 6%. The company revised its full-year revenue guidance to between $202 million and $205 million, with EBITDA guidance at $41 million to $45 million. These are recent developments, reflecting the company's strategic execution, including attracting larger clients and expanding product offerings.

Enfusion's management team expressed confidence in achieving its medium-term revenue growth target of 20% to 22% from 2025 to 2027. The company expects to maintain a consistent margin with EBITDA guidance refined to $41 million to $45 million. Despite some moderation in back book growth and a slight deceleration of ARR growth, Enfusion remains optimistic about its positioning for future growth through product innovation, strategic partnerships, and improved forecasting processes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.